Predictors of recurrence in thymic tumors: Importance of invasion, World Health Organization histology, and size  by Wright, Cameron D. et al.
Wright et al General Thoracic SurgeryPredictors of recurrence in thymic tumors: Importance of
invasion, World Health Organization histology, and size
Cameron D. Wright, MD, John C. Wain, MD, Daniel R. Wong, MD, MPH, Dean M. Donahue, MD,
Henning A. Gaissert, MD, Hermes C. Grillo, MD, and Douglas J. Mathisen, MD
G
TSFrom the Division of General Thoracic
Surgery, Massachusetts General Hospital,
Department of Surgery, Harvard Medical
School, Boston, Mass.
Read at the Eighty-fifth Annual Meeting of
The American Association for Thoracic
Surgery, San Francisco, Calif, April 10-13,
2005.
Received for publication April 4, 2005; re-
visions received June 27, 2005; accepted
for publication July 11, 2005.
Address for reprints: Cameron D. Wright,
MD, Blake 1570, Massachusetts General
Hospital, Boston, MA 02114 (E-mail:
wright.Cameron@mgh.harvard.edu).
J Thorac Cardiovasc Surg 2005;130:1413-21
0022-5223/$30.00
Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.07.026
TObjective: This study sought to define predictors of recurrence after resection of
thymic tumors.
Methods: A single-institution retrospective study was performed of 179 patients
who underwent resection of a thymic tumor from 1972 through 2003.
Results: Resection was complete in 90% (161/179) of patients. After a median
follow-up of 115 months, the recurrence rate was 11% (20/179), the tumor-related
death rate was 7.8% (14/179), and the overall death rate was 36.3% (65/179). Tumor
recurrence correlated with advanced stage and histology (P  .0001). The differ-
ence in recurrence between Masaoka stage I (0) and II (1.7% [1/59]) was insignif-
icant. Recurrence rates correlated with World Health Organization tumor type: A
and AB, 0%; B1 and B2, 8% (4/51); B3, 27% (14/51); and C, 50% (2/4; P .0001).
Tumor size separation into quintiles demonstrated a step-up of recurrence at 8 cm
(8 cm, 1.8% [2/113]; 8 cm, 28% [18/64]; P .003). Multivariate Cox modeling
demonstrated that Masaoka stage (odds ratio, 5.70; P  .001), World Health
Organization histology (odds ratio, 5.77; P  .003), and size (odds ratio, 1.16; P 
.001) were independent predictors of recurrence.
Conclusion: The Masaoka staging system could be collapsed to 3 degrees of
invasion by combining stages I and II. The World Health Organization histologic
type can be simplified for clinical use into A (A, AB), early B (B1, B2), advanced
B (B3), and C tumors. Size of 8 cm or larger is an independent risk factor, even
when patients with Masaoka stage III tumors are considered alone, and might
identify candidates for preoperative therapy.
Previous reports suggest the best predictors of outcome in thymoma areMasaoka stage (a surrogate marker for the biologic aggressiveness of thetumor), the World Health Organization (WHO) histologic classification sys-
tem, and the performance of a complete resection.1-10 Some studies report that great
vessel invasion and larger size also predict a poor prognosis.3,4,6,7 Older reports of
risk factors must be judged with caution because of inadequate statistical evaluation,
lack of prolonged follow-up (10 years’ follow-up is needed to evaluate for
possible recurrence), and use of overall survival rather than the more accurate
thymoma-related survival. Although the Masaoka staging system is the most com-
monly used, several other schemes have been proposed and used.11,12 Several
groups have reported on the lack of any significant difference between Masaoka
stages I and II.2 Indeed, the original report by Masaoka did not demonstrate any
difference between stages I and II.13 Several groups have proposed consideration of
both Masaoka stage and WHO histology in estimating prognosis because either is an
independent predictor of recurrence and death from thymoma.1,2,5-7,9,10 With a
relatively large database of patients with thymoma, we sought to define the best
discriminators of prognosis and how they might be used in a staging system. We
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it would be readily available to the clinician at the time of
diagnosis and thus could guide preoperative therapy. Fur-
thermore, we decided to emphasize recurrences over deaths
because death is not inevitable if there is a recurrence, and
recurrence might precede death by many years. Selecting
recurrence rather than death also improves modeling be-
cause more events are analyzed.
Patients and Methods
From 1972 through 2003, 179 patients underwent transsternal
resection of a thymic tumor (thymoma or thymic carcinoma) at the
Massachusetts General Hospital. Five patients who underwent
exploration or debulking only in the same time period were ex-
cluded. Resection encompassed the tumor, the entire thymus, the
mediastinal fat from one phrenic nerve to the other, and all invaded
adjacent structures. Eight patients with difficult-to-resect tumors
had induction therapy: 5 had radiation alone (30-45 Gy), 1 had
chemotherapy alone (cisplatin and etoposide), and 2 had chemo-
radotherapy (45 Gy, cisplatin and etoposide). Postoperative radi-
ation (n 69 patients) was given for close or positive margins and
at the discretion of the radiation oncologist for invasive tumors
(50-60 Gy). A database of patients with thymoma has been main-
tained at the Massachusetts General Hospital since the first report
in 1970. Some of these patients form the basis of previous reports.2
Data from patient records were abstracted and recorded as vari-
ables, as seen in Table 1. Survival and recurrence information has
been collected through patient or relative contact, contact with
personal physicians, and examination of death records. Median
follow-up was 115 months, follow-up has been completed in 96%
of patients, and only 6 patients were lost to follow-up at 2, 3, 6, 78,
80, and 120 months, respectively. Approval for this study was
granted by the institutional review board.
Comparison between groups of categoric variables were made
by using the 2 statistic. The Kaplan-Meier method was used to
estimate the disease-free survival, thymoma-related survival, and
overall survival. The log-rank test was used to compare survival of
different groups. The Cox proportional hazards regression model
was used to determine prognostic variables. Logistic regression
was used to model binary outcomes. Multivariable models with
stepwise entry criteria (0.10 to enter and 0.05 to retain) with
manual oversight were constructed by using both proportional
hazards and logistic regression analysis for selected variables, with
univariable significance at the P  .10 level. Receiver operating
characteristic curves were generated for logistic models, and the
c-statistic was calculated. The Hosmer-Lemeshow test was calcu-
lated for the final models. Bootstrap analysis (n  1000) was used
Abbreviations and Acronyms
CI  confidence interval
OR  odds ratio
WHO World Health Organizationto test the validity of the model.
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Patient characteristics are listed in Table 1. There were 59
Masaoka stage 2 tumors: 40 with macroscopic invasion and
19 with microscopic invasion of the capsule. There were 45
Masaoka stage 3 tumors: 43 invaded the pleura, 14 invaded
the great vessels, 37 invaded the pericardium, and 25 in-
vaded the lung. There were 11 Masaoka stage 4 tumors: 11
had pleural metastases, and 2 had pericardial metastases.
Two patients died after resection (1 of stroke and 1 of
pulmonary embolism). Complete resection were performed
in 90% (161/179) of patients. Ten-year thymoma-related
survival was 92% (95% confidence interval [CI], 88%-
97%), whereas 10-year overall survival was only 71% (95%
CI, 64%-79%). Fourteen patients died of persistence or
recurrence of the thymoma, which represented only 22%
(14/65) of late deaths. Ten-year disease-free survival was
87% (95% CI, 82%-93%). Twenty (11%) of 179 patients
had a recurrence: pleural implants, 16; mediastinal, 2; and
distant, 2. Sixty percent (12/20) of recurrences were within
5 years, and 40% (8/20) were beyond 5 years.
Table 1 summarizes the results of the univariable anal-
ysis of prognostic factors on recurrence and thymoma death
rates. The invasion variables (pleural, lung, pericardial, or
great vessel invasion) were studied, and all were highly
correlated (all P  .0001). All invasion variables were
associated with recurrence and death. No individual inva-
sion parameter stood out as a better predictor of recurrence
or death. WHO histology was also highly correlated with
Masaoka stage (P  .0001). Tumor size was highly corre-
lated with stage (P  .0001), histology (P  .015), and
complete resection (P  .009). Increasing size was associ-
ated with recurrence and death. When size was divided into
quintiles, there was a clear step-up in recurrences at 8 cm
(P  .003) by means of logistic regression analysis (Table
2). This threshold of tumor size was also seen on a time-
to-event analysis, with a wide separation at 8 cm (Figure 1).
Tumors of 8 cm or larger were more likely to be Masaoka
stage III or IV (35/56 [62.5%] of all stage III or IV tumors)
than Masaoka stage I or II (29/121 [23.9%] of all stage I or
II tumors; P  .0001). Tumors of 8 cm or larger were more
likely to be WHO type B1 or greater (46/105 [43.8%] of all
B1 or greater tumors) than A or AB (18/72 [25%] of all A
or AB tumors; P  .035). Masaoka stage stratified recur-
rence relatively well (P  .0001, Figure 2). There was no
difference in recurrence between stages I and II or between
stages IIa and IIb. There was a large step-up in risk between
stages I and II and the later 2 stages (Table 3). WHO type
A and AB tumors acted in a benign fashion, with no
recurrences or deaths (Figure 3 and Table 4). WHO type B
tumors did recur, especially B3 tumors. B1 and B2 tumors
had an 8% (4/51) recurrence rate, which was in contrast to
B3 tumors with a 27% (14/51) recurrence rate. Type C
tumors had a 50% (2/4) recurrence rate.
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rence. Cox proportional hazards analysis indicated that
Masaoka stage (odds ratio [OR], 5.70; P  .0001), WHO
histology (OR, 5.77; P  .003), and size (OR, 1.16; P 
.001) were independent predictors. The results of the mul-
TABLE 1. Patient characteristics and univariable analysis
Variable
Overall
(n  179)
No recurrence
(n  159)
Recurrence
(n  20)
Age
40 150 (83.8) 137 (86.2) 13 (65.0)
50 129 (72.1) 119 (74.8) 10 (50.0)
60 84 (46.9) 78 (49.1) 6 (30.0)
70 39 (21.8) 37 (23.3) 2 (10.0)
Male sex 85 (47.5) 74 (46.5) 11 (55.0)
MG 53 (29.6) 49 (30.8) 4 (20.0)
Other para 2 (1.1) 1 (0.6) 1 (5.0)
Symptoms 98 (54.8) 82 (51.6) 16 (80.0)
Complete
Resection
161 (89.9) 150 (94.3) 11 (55.0)
Invasion
Pleural 62 (34.6) 43 (27.0) 19 (95.0)
Great vessel 17 (9.5) 11 (6.9) 6 (30.0)
Pericardial 47 (26.3) 28 (17.6) 19 (95.0)
Lung 34 (19.0) 21 (13.2) 13 (65.0)
Size
Mean 7.2 3.9 6.7 3.12 11.0 6.4
Median 7.0 6.0 9.5
5 cm 115 (65.0) 96 (61.2) 19 (95.0)
8 cm 64 (35.8) 46 (28.9) 18 (90.0)
10 cm 37 (20.9) 27 (17.2) 10 (50.0)
WHO
A 21 (11.7) 21 (13.2) 0
AB 52 (29.0) 52 (32.7) 0
B1 27 (15.1) 25 (15.7) 2 (10.0)
B2 24 (13.4) 22 (13.8) 2 (10.0)
B3 51 (28.5) 37 (23.3) 14 (70.0)
C 4 (2.2) 2 (1.3) 2 (10.0)
Masaoka
I 64 (35.8) 64 (40.2) 0
II 59 (33.0) 58 (36.5) 1 (5.0)
III 45 (25.1) 31 (19.5) 14 (70.0)
IV 11 (6.2) 6 (3.8) 5 (25.0)
This table lists the recurrence rate and thymoma death rate for various p
unless otherwise specified (*t test or Wilcoxon rank sum test). MG, Mya
TABLE 2. Recurrence rate as a function of size
Size quintiles: 1 (1.0-4.0 cm) 2 (4.5-5.0 cm)
N 37 25
Recurrence, n (%) 0 1 (4.0)
Unadjusted OR (95% CI) 1.00
P value —Note the separation at 8 cm and beyond. The same result was seen when size
The Journal of Thoracictivariable logistic model were quite similar, with the same
variables identified as significant (data not shown). When
this model was restricted to patients with Masaoka stage III
tumors only, size of 8 cm or larger remained a good pre-
dictor of recurrence (OR, 13.9; P .02). Receiver operating
rognostic factors
value
Thymoma death
(n  14)
No thymoma death
(n  165) P value
.03 140 (84.8) 10 (71.4) .46
.07 121 (73.3) 8 (57.1) .52
.25 80 (48.5) 4 (28.6) .42
.27 38 (23.0) 1 (7.1) .32
.59 77 (46.7) 8 (57.1) .53
.18 49 (29.7) 4 (28.6) .58
.0001 1 (0.6) 1 (7.1) .0007
.02 86 (52.1) 12 (85.7) .02
.0001 153 (92.7) 8 (57.1) .0001
.0001 49 (29.7) 13 (92.9) .0001
.0003 11 (6.7) 6 (42.9) .0001
.0001 34 (20.6) 13 (92.9) .0001
.0001 26 (15.8) 8 (57.1) .0001
.007* 6.8 3.1 11.8 7.5 .03*
.0001* 6.0 10.0 .0002*
.0001 102 (62.6) 13 (92.9) .02
.0001 52 (31.5) 12 (85.7) .0001
.004 29 (17.8) 8 (57.1) .0001
.0001 21 (12.7) 0 .0001
52 (31.5) 0
25 (15.2) 2 (14.3)
23 (13.9) 1 (7.1)
42 (25.4) 9 (64.3)
2 (1.2) 2 (14.3)
.0001 64 (38.8) 0 .0001
58 (35.2) 1 (7.1)
35 (21.2) 10 (71.4)
8 (72.7) 3 (21.4)
ial prognostic factors. P values were obtained by using the log-rank test
ia gravis; Other para, other paraneoplastic syndromes.
3 (6.0-7.0 cm) 4 (8.0-9.0 cm) 5 (10.0-36.0 cm)
51 27 37
1 (2.0) 8 (29.6) 10 (27.0)
1.26 (0.08-20.6) 26.5 (3.1-225.7) 23.3 (2.80-191.4)
.87 .003 .003of p
P









otentwas divided into deciles. OR, Odds ratio; 95% CI, 95% confidence interval.
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and are seen in Figure 4. The c statistic (area under the
curve) was 0.92, and the Hosmer-Lemeshow test result was
0.95 when all 3 variables (stage, histology, and size) were in
the model. Bootstrap analysis demonstrated that only
Masaoka stage remained robust (P  .0001) in predicting
recurrence, whereas WHO histology (P  .35) and size
(P  .15) did not. Multivariable models were also con-
structed to predict thymoma deaths. Size (OR, 1.09; P 
.02), WHO histology (OR, 7.68; P  .004), and Masaoka
stage (OR, 4.54; P  .002) again were found to be signif-
icant in a Cox proportional hazards model. Patients who had
postoperative radiation had a higher recurrence and death
from thymoma rate (both .0001), but this finding was not
significant in the multivariable model. Because of the long
time period of the study, the data set was divided into 2 time
periods (before and after 1990) to examine the effects of the
time period on results. Stage, histology, and size did not
change significantly with time. There was no difference in
recurrence rate between the 2 time periods.
Discussion
Masaoka stage was a strong independent predictor of thy-
Figure 1. Kaplan-Meier estimate of recurrence as a fu
at risk at 0, 10, and 20 years for each stratum is givenmoma recurrence, a result expected from a descriptor of
1416 The Journal of Thoracic and Cardiovascular Surgery ● Novinvasion. However, there was no clinical difference between
stages I and II, an observation shared by several recent
reports.1,2,6,7,9,10 Because the objective of a staging scheme
is to separate different groups of patients according to
prognosis, the Masaoka system can be consolidated into 3
stages, combining stages I and II. No single invasion vari-
able independently predicted recurrence, a finding ex-
plained by their inclusion into the Masaoka stage. Although
some previous reports found great vessel invasion to be an
independent predictor, our analysis does not.4 This is per-
haps due to the small number of involved patients, the
favorable response to adjuvant treatment, and the high cor-
relation with the other invasion variables. Most reports
indicate that complete resection is an independent risk fac-
tor. Complete resection was a strong univariable but not an
independent predictor in our analysis. Again, we suspect the
small number of patients with incomplete resection, a fa-
vorable response to adjuvant treatment, and confounding
with the 3 multivariable predictors. There were too few
patients who had induction therapy to ascertain the efficacy
of preoperative treatment. The influence of adjuvant radia-
tion on recurrence was not fully examined in this report, but
2 recent reports from our center suggest there is a question-
n of size. Note the clear separation at 8 cm. Number
arentheses.nctio
in pable role for radiation in patients who have stage 2 or 3
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ysis demonstrated that adjuvant radiation was not a predic-
tor of recurrence or death.
WHO histology was also an independent predictor of
thymoma recurrence, which is not surprising because his-
tology is strongly correlated with tumor invasiveness and
thus Masaoka stage. Several recent reports concur with this
observation and add support to consider WHO histology in
estimating prognosis.1,2,5-10 Although there are 6 histologic
types of thymic tumors, the clinical grouping of these tu-
mors could probably be simplified for clinical use into 4
groups with a similar prognosis: A (A and AB), early B (B1
and B2), B3, and C. Type B3 and C tumors are very
aggressive and essentially always require multimodality
treatment. Two extremes of histology can serve as examples
as to how treatment and prognosis might be refined. One
example might be a patient with a Masaoka stage II tumor
that is a type A. The prognosis should be excellent, with
little chance adjuvant therapy would improve the result.
Alternatively, a stage III type B3 tumor is at much greater
risk of recurrence, the prognosis is more guarded, and
multimodality therapy should be strongly considered.
Tumor size was an independent predictor of recurrence,
Figure 2. Kaplan-Meier estimate of recurrence as a fu
years for each stratum is given in parentheses.and there is a threshold size that is clinically useful. Size is
The Journal of Thoracicintuitively correlated with degree of invasion and worse
histology. Indeed, that was the case in our data set, in which
size of 8 cm or greater was associated with advanced stage
and worse histology. Other studies have demonstrated that
larger tumors have a worse prognosis but have not investi-
gated the relationship in detail.3,7 Our findings suggest a
threshold effect at 8 cm, with a marked increase in recur-
rence compared with smaller tumors. This association per-
sisted even when only Masaoka stage III tumors were
considered. The relationship between size and prognosis
could be clinically useful because it is the one variable that
can be known for sure before resection to guide therapy.
TABLE 3. Recurrence rate as a function of Masaoka stage
Masaoka stage: I II III IV
N 64 59 45 11
Recurrence,
n (%)
0 1 (1.7) 14 (31.1) 5 (45.4)
Unadjusted OR
(95% CI)
1.00 55.1 (7.0-434.8) 101.6 (10.2-999.9)
P value — .0001 .0001
on of Masaoka stage. Number at risk at 0, 10, and 20nctiOR, Odds ratio; 95% CI, 95% confidence interval.
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because invasion is difficult to differentiate from simple
abutment on the computed tomographic scan. Because
Masaoka stage assignment is unreliable before resection,
another surrogate marker of poor prognosis would be help-
ful. Tumor size would be a good preoperative predictor
because it is easily determined. Recent reports suggest a
survival advantage to induction therapy of stage III thymo-
mas, as opposed to adjuvant treatment.16-18 Tumors of less
than 8 cm without evidence of invasion on computed tomog-
raphy would be resected for both diagnosis and therapy. Tu-
mors of 8 cm or larger (or those rare tumors 8 cm that have
evidence of invasion suggestive of stage III) would be candi-
Figure 3. Kaplan-Meier estimate of recurrence as a
Number at risk at 0, 10, and 20 years for each stratum
TABLE 4. Recurrence rate as a function of WHO histology
WHO histology: A AB B1
N 21 52 27
Recurrence, n (%) 0 0 2 (7.4)
Unadjusted OR (95% CI) 1.00
P value —
B1 was combined with A and AB because there were no events for the latte
interval.
1418 The Journal of Thoracic and Cardiovascular Surgery ● Novdates for induction therapy to be followed by resection. A core
cutting biopsy would need to be performed before induction
therapy, and this information could be further used to eliminate
overtreatment of patients with good prognoses. The occasional
large tumor that also happens to be a type A (A or AB) tumor
could be spared induction therapy, whereas a type B or C
tumor would proceed to induction therapy. The c statistic for
this information (size and histology) is 0.90, which is clinically
very acceptable and close to c statistic of 0.92 for the full
model with all 3 variables.
There are several limitations of our study. Death is a hard
end point, but it is possible that a few patients who died of
other causes also had an asymptomatic thymoma recurrence
tion of World Health Organization (WHO) histology.
iven in parentheses.
B2 B3 C
24 51 4
2 (8.3) 14 (27.4) 2 (50.0)
4.46 (0.60-33.4) 18.5 (4.0-85.5) 49.0 (4.4-544.8)
.15 .0002 .002
. WHO, World Health Organization; OR, odds ratio; 95% CI, 95% confidencefunc
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artificially raised the recurrence-free survival. Not all pa-
tients were carefully followed beyond 5 years after resec-
tion, such that although they might have been asymptomatic
when they were contacted for follow-up, they could have
had an early recurrence that was not clinically manifest yet.
This would artificially improve the recurrence rate and
recurrence-free survival. This was a single-institution expe-
rience, and therefore this data set might not be readily
applicable to all patients with thymic tumors. Our data set
was weighted with low-risk patients with stage I and II
tumors, which thus lowered the recurrence rate and hence
our ability to robustly model recurrence. This was born out
in our bootstrap analysis of the recurrence model, which
only confirmed Masaoka stage and not size or histology in
the model prediction. This result is not that surprising with
only 179 patients and only 20 events in the data set. How-
ever, several other recent well-analyzed studies have also
found these variables to be important, and therefore it is
very likely these are clinically relevant.
Recurrences are uncommon after resection of a thy-
Figure 4. Receiver operating characterismoma. Most deaths after thymoma resection are due to
The Journal of Thoracicother causes than tumor recurrence. There was no important
difference in recurrences or deaths between Masaoka stage
I and II tumors, and therefore there is little value in sepa-
rating these 2 similar groups of patients. Masaoka stage is
highly correlated with WHO histology and size. The WHO
histologic groups could be clinically simplified from 6
groupings to 4: A (A and AB), early B (B1 and B2), B3, and
C. Tumors of 8 cm or larger have a significantly increased
recurrence rate. A model containing the variables Masaoka
stage, WHO histology, and size predicts recurrence in a
reliable fashion. Size might be a valuable preoperative pre-
dictor to help decide which patients might benefit from
induction therapy.
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Discussion
Dr Frank C. Detterbeck (Chapel Hill, NC). I compliment you on
a nice study.
I think there are several aspects of this article that really
deserve some emphasis. First is the consideration of the end points.
I certainly agree wholeheartedly that overall survival is a poor end
point in studies regarding thymoma, and we really need to be
looking at recurrence or disease-free survival. Second, the need for
prolonged follow-up, as you have in your study, is critically
important. I think these are major aspects that need to be empha-
sized.
Another important aspect is that you have attempted to arrive at
insights that can guide us in the management of future patients.
Certainly the study has analyzed features that are available post-
operatively, such as the Masaoka stage or the WHO histologic
1420 The Journal of Thoracic and Cardiovascular Surgery ● Novsubtype, but I compliment you for trying to take this a step further
and using what we can get from this to try to guide us with regard
to patients we see preoperatively. This is particularly important
because I think there are more and more compelling data, includ-
ing from your own institution, that preoperative chemotherapy for
high-risk patients is beneficial.
Certainly one of the characteristics, as you pointed out, was that
size was a marker of poor outcomes, and that is easy to assess
preoperatively, or at least we are pretty comfortable that we can
assess it accurately preoperatively. However, I do think a word of
caution is warranted. Of 6 larger series of thymomas in which the
prognostic value of size was assessed by means of multivariate
analysis, 3 found this to be an independent predictor and 3 did not
with regard to overall survival. With regard to recurrence, this
study is the only one that demonstrated significance to size,
whereas 3 others, including an earlier one from Massachusetts
General Hospital, did not.
Masaoka stage has certainly been found to be an independent
predictor of survival in really every multivariate analysis that has
assessed this. The problem is that no study has really analyzed how
reliable a preoperative scan is in determining the actual Masaoka
stage. The clinical impression that many of us have is that it is
difficult to differentiate abutment versus actual invasion. Therefore
one of my questions, Dr Wright, is whether you have any data
regarding how reliable the preoperative assessment of stage was
compared with what was actually found.
Dr Wright. We actually did not assign a stage preoperatively
to these patients. As you say, the Masaoka system is a surgical
staging system, and therefore it is a postoperative value. Obvi-
ously, clinical intuition is used to estimate whether a complete
resection can be done (ie, stage I or II), but we did not assign that
value preoperatively.
Dr Detterbeck. The third factor of significance in your study is
the WHO histologic classification. I am personally still struggling
to understand the exact value of this classification and how best to
use it. Previous systems were rather inconsistent between different
pathologists, and in general, the multivariate analyses did not
suggest independent significance. Now 5 of 8 studies, including
this one, that have looked at the value of the WHO system and
Masaoka stage have found it to be prognostically significant.
However, in looking at the details of these studies, the most
consistent message is that type C has a poor prognosis, a minority
of studies have suggested that type B3 is intermediate, and the
results for the other types (A, AB, B1, and B2) are rather incon-
sistent among studies. You have suggested that A and AB are
better than B1 and B2, but other studies have really not found that.
It might be that the histologic heterogeneity of tumors is a
problem. There was a study by Moran and Suster that suggested
that you needed to have at least 5 slides examined to be able to
accurately assess that. Therefore how many slides did you look at
to assess the stage or the histologic subtype?
Dr Wright. Well, I cannot answer that question. But as you are
probably aware, Nancy Harris is our director of surgical pathology,
and she is an expert on thymoma. She had Professor Muller-
Hermelink come over to our institution to educate our pathologists
on how to use his classification system, and all of the slides were
reviewed by Professor Muller-Hermelink. Every thymoma case is
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good, but I am not a pathologist.
Dr Detterbeck. I think the biggest problem is our ability to
determine the subtype preoperatively. Do you have any data re-
garding how often a preoperative core-needle biopsy actually
correlated with the histologic subtype in an actual resection spec-
imen?
Dr Wright. I do not have that actual information. There is no
question that there is a potential bias of sampling error the smaller
the biopsy is in thymomas, and that can be a potentially major
clinical problem that definitely confounds proper histologic typing
of tumors preoperatively.
Dr Detterbeck. Finally, how should we actually use the his-
tologic classification? Most of the data for chemotherapy have
really involved preoperative chemotherapy. Are we really justified
in using histologic subtype to guide us with regard to postoperative
adjuvant therapy? What do you think?
Dr Wright. Well, I think the extremes can be helpful, and the
middle is a hard ground.
Some type A tumors can be quite big, you know, well over 10 cm.
That is one of the anomalies of our particular data set, and this has
been noticed by other authors. But if I have an A tumor and I know
about it either preoperatively or postoperatively, I know that they
are clinically benign and rarely recur, and I would not give that
patient induction or adjuvant therapy. If I had a large B3 tumor, I
would recommend induction therapy because they have a high
chance of recurrence.
Dr Federico Venuta (Rome, Italy). Congratulations on your
study.
This is a retrospective study, and you started to evaluate the
results with patients who were operated on more than 30 years ago.
I am sure you changed your policy at least a little in this period of
The Journal of Thoracictime according to the indications for postoperative chemotherapy
and radiotherapy and induction chemotherapy. How did you
change your policy in this period of time? Did you try to stratify
your results according to the time when the operation was done?
Dr Wright. We stratified our results in half and looked at the
early versus late global results, and there was no difference in
recurrence rate or death rate caused by thymoma. In the last 5 years
or so, we have increasingly started with induction chemotherapy or
chemoradiotherapy for patients who we think, as you do, are
poorly resectable, but that is a relatively small number of patients.
As you know, we have published several series now looking at the
influence of adjuvant radiation therapy, and there seems to be no
meaningful improvement in recurrence or disease-free survival
with postoperative adjuvant radiotherapy, and that was not a uni-
variate or a multivariate predictor of recurrence. I applaud your
results, Dr Venuta, of the prospective treatment of these patients,
and that is what I think we need to move to. I am suggesting that
8 cm might be a reasonable way to start.
Dr David J. Sugarbaker (Boston, Mass). Because you have
really extensive experience with this problem, could you comment
on lymph node involvement and its effect on survival?
Dr Wright. Well, there was a TNM system proposed by one of
our Japanese colleagues several years ago in thymoma, but the
problem was that there were so few patients who had lymph nodes
involved. In our experience it is only the B3 tumors or C tumors
that had lymph nodes involved, and therefore it was not clinically
useful in terms of stratification. In thymic carcinoma it is an
important prognostic factor.
Dr Sugarbaker. Therefore if you find it, you can consider it
sort of incidental, and, in your well-studied opinion, both clinically
and from the literature, it is just not that important here?Dr Wright. Yes, that is true for thymoma.
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